Official reprint from UpToDate®
www.uptodate.com ©2016 UpToDate®

HLA and ABO sensitization and desensitization in renal transplantation

Christina L Klein, MD
Daniel C Brennan, MD, FACP
Section Editor
Barbara Murphy, MB, BAO, BCh, FRCPI
Deputy Editor
Albert Q Lam, MD


Despite a marked increase in the number of living-donor allografts (LDAs) performed annually, many potential recipients with otherwise suitable donors are relegated to the ever-expanding deceased-donor waiting list secondary to either:

Preformed human leukocyte antigen (HLA) antibodies. These are acquired via pregnancy, transfusion, or prior transplant.


ABO blood group incompatibility (ABOI).

If not adequately removed, the presence of such antibodies is likely to result in severe antibody-mediated rejection (AMR) and early graft loss. AMR or "humoral" rejection was recognized early in the history of transplantation as hyperacute rejection caused by the presence of preformed antibodies ("humors") to donor blood group ABO or HLA. Introduction of pretransplant crossmatch techniques and the use of ABO-compatible donors essentially eliminated hyperacute rejection.


Subscribers log in here

To continue reading this article, you must log in with your personal, hospital, or group practice subscription. For more information or to purchase a personal subscription, click below on the option that best describes you:
Literature review current through: Sep 2016. | This topic last updated: Apr 25, 2016.
The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use ©2016 UpToDate, Inc.
  1. 2008 OPTN/SRTR Annual Report: Transplant Data 1998-2007 www.ustransplant.org (Accessed on February 10, 2010).
  2. Glotz D, Antoine C, Duboust A. Antidonor antibodies and transplantation: how to deal with them before and after transplantation. Transplantation 2005; 79:S30.
  3. Takahashi K, Saito K, Takahara S, et al. Excellent long-term outcome of ABO-incompatible living donor kidney transplantation in Japan. Am J Transplant 2004; 4:1089.
  4. Tanabe K, Takahashi K, Agishi T, et al. Removal of anti-A/B antibodies for successful kidney transplantation between ABO blood type incompatible couples. Transfus Sci 1996; 17:455.
  5. Tanabe K, Takahashi K, Sonda K, et al. Long-term results of ABO-incompatible living kidney transplantation: a single-center experience. Transplantation 1998; 65:224.
  6. Gloor JM, Lager DJ, Moore SB, et al. ABO-incompatible kidney transplantation using both A2 and non-A2 living donors. Transplantation 2003; 75:971.
  7. Sonnenday CJ, Warren DS, Cooper M, et al. Plasmapheresis, CMV hyperimmune globulin, and anti-CD20 allow ABO-incompatible renal transplantation without splenectomy. Am J Transplant 2004; 4:1315.
  8. Tydén G, Kumlien G, Genberg H, et al. ABO incompatible kidney transplantations without splenectomy, using antigen-specific immunoadsorption and rituximab. Am J Transplant 2005; 5:145.
  9. Tanabe K. Japanese experience of ABO-incompatible living kidney transplantation. Transplantation 2007; 84:S4.
  10. Opelz G, Morath C, Süsal C, et al. Three-year outcomes following 1420 ABO-incompatible living-donor kidney transplants performed after ABO antibody reduction: results from 101 centers. Transplantation 2015; 99:400.
  11. Toki D, Ishida H, Horita S, et al. Blood group O recipients associated with early graft deterioration in living ABO-incompatible kidney transplantation. Transplantation 2009; 88:1186.
  12. Norman DJ, Prather JC, Alkhunaizi AM, et al. Use of A(2) kidneys for B and O kidney transplant recipients: report of a series of patients transplanted at a single center spanning a decade. Transplant Proc 2001; 33:3327.
  13. Stegall MD, Dean PG, Gloor JM. ABO-incompatible kidney transplantation. Transplantation 2004; 78:635.
  14. Alkhunaizi AM, de Mattos AM, Barry JM, et al. Renal transplantation across the ABO barrier using A2 kidneys. Transplantation 1999; 67:1319.
  15. Shimmura H, Tanabe K, Ishikawa N, et al. Role of anti-A/B antibody titers in results of ABO-incompatible kidney transplantation. Transplantation 2000; 70:1331.
  16. Breimer ME, Samuelsson BE. The specific distribution of glycolipid-based blood group A antigens in human kidney related to A1/A2, Lewis, and secretor status of single individuals. A possible molecular explanation for the successful transplantation of A2 kidneys into O recipients. Transplantation 1986; 42:88.
  17. Nelson PW, Landreneau MD, Luger AM, et al. Ten-year experience in transplantation of A2 kidneys into B and O recipients. Transplantation 1998; 65:256.
  18. Sorensen JB, Grant WJ, Belnap LP, et al. Transplantation of ABO group A2 kidneys from living donors into group O and B recipients. Am J Transplant 2001; 1:296.
  19. Bryan CF, Winklhofer FT, Murillo D, et al. Improving access to kidney transplantation without decreasing graft survival: long-term outcomes of blood group A2/A2B deceased donor kidneys in B recipients. Transplantation 2005; 80:75.
  20. Hurst FP, Sajjad I, Elster EA, et al. Transplantation of A2 kidneys into B and O recipients leads to reduction in waiting time: USRDS experience. Transplantation 2010; 89:1396.
  21. Bryan CF, Nelson PW, Shield CF 3rd, et al. Transplantation of A2 and A2B kidneys from deceased donors into B waiting list candidates increases their transplantation rate. Clin Transpl 2004; :127.
  22. http://optn.transplant.hrsa.gov/ContentDocuments/OPTN_Policies.pdf.
  23. Ishida H, Miyamoto N, Shirakawa H, et al. Evaluation of immunosuppressive regimens in ABO-incompatible living kidney transplantation--single center analysis. Am J Transplant 2007; 7:825.
  24. Tydén G, Donauer J, Wadström J, et al. Implementation of a Protocol for ABO-incompatible kidney transplantation--a three-center experience with 60 consecutive transplantations. Transplantation 2007; 83:1153.
  25. Montgomery RA, Locke JE, King KE, et al. ABO incompatible renal transplantation: a paradigm ready for broad implementation. Transplantation 2009; 87:1246.
  26. Habicht A, Bröker V, Blume C, et al. Increase of infectious complications in ABO-incompatible kidney transplant recipients--a single centre experience. Nephrol Dial Transplant 2011; 26:4124.
  27. Sharif A, Alachkar N, Bagnasco S, et al. Incidence and outcomes of BK virus allograft nephropathy among ABO- and HLA-incompatible kidney transplant recipients. Clin J Am Soc Nephrol 2012; 7:1320.
  28. Lentine KL, Axelrod D, Klein C, et al. Early clinical complications after ABO-incompatible live-donor kidney transplantation: a national study of Medicare-insured recipients. Transplantation 2014; 98:54.
  29. Padmanabhan A, Ratner LE, Jhang JS, et al. Comparative outcome analysis of ABO-incompatible and positive crossmatch renal transplantation: a single-center experience. Transplantation 2009; 87:1889.
  30. Toki D, Ishida H, Setoguchi K, et al. Acute antibody-mediated rejection in living ABO-incompatible kidney transplantation: long-term impact and risk factors. Am J Transplant 2009; 9:567.
  31. Alexandre GP, De Bruyere M, Squifflet JP, et al. Human ABO-incompatible living donor renal homografts. Neth J Med 1985; 28:231.
  32. Alexandre GP, Squifflet JP, De Bruyère M, et al. Present experiences in a series of 26 ABO-incompatible living donor renal allografts. Transplant Proc 1987; 19:4538.
  33. Ishida H, Koyama I, Sawada T, et al. Anti-AB titer changes in patients with ABO incompatibility after living related kidney transplantations: survey of 101 cases to determine whether splenectomies are necessary for successful transplantation. Transplantation 2000; 70:681.
  34. Gloor JM, Lager DJ, Fidler ME, et al. A Comparison of splenectomy versus intensive posttransplant antidonor blood group antibody monitoring without splenectomy in ABO-incompatible kidney transplantation. Transplantation 2005; 80:1572.
  35. Sawada T, Fuchinoue S, Kawase T, et al. Preconditioning regimen consisting of anti-CD20 monoclonal antibody infusions, splenectomy and DFPP-enabled non-responders to undergo ABO-incompatible kidney transplantation. Clin Transplant 2004; 18:254.
  36. Sawada T, Fuchinoue S, Teraoka S. Successful A1-to-O ABO-incompatible kidney transplantation after a preconditioning regimen consisting of anti-CD20 monoclonal antibody infusions, splenectomy, and double-filtration plasmapheresis. Transplantation 2002; 74:1207.
  37. Toki D, Ishida H, Horita S, et al. Impact of low-dose rituximab on splenic B cells in ABO-incompatible renal transplant recipients. Transpl Int 2009; 22:447.
  38. Macklin PS, Morris PJ, Knight SR. A systematic review of the use of rituximab for desensitization in renal transplantation. Transplantation 2014; 98:794.
  39. Lo P, Sharma A, Craig JC, et al. Preconditioning Therapy in ABO-Incompatible Living Kidney Transplantation: A Systematic Review and Meta-Analysis. Transplantation 2016; 100:933.
  40. Segev DL, Simpkins CE, Warren DS, et al. ABO incompatible high-titer renal transplantation without splenectomy or anti-CD20 treatment. Am J Transplant 2005; 5:2570.
  41. Locke JE, Zachary AA, Haas M, et al. The utility of splenectomy as rescue treatment for severe acute antibody mediated rejection. Am J Transplant 2007; 7:842.
  42. Park WD, Grande JP, Ninova D, et al. Accommodation in ABO-incompatible kidney allografts, a novel mechanism of self-protection against antibody-mediated injury. Am J Transplant 2003; 3:952.
  43. Onitsuka S, Yamaguchi Y, Tanabe K, et al. Peritubular capillary deposition of C4d complement fragment in ABO-incompatible renal transplantation with humoral rejection. Clin Transplant 1999; 13 Suppl 1:33.
  44. Haas M, Rahman MH, Racusen LC, et al. C4d and C3d staining in biopsies of ABO- and HLA-incompatible renal allografts: correlation with histologic findings. Am J Transplant 2006; 6:1829.
  45. Setoguchi K, Ishida H, Shimmura H, et al. Analysis of renal transplant protocol biopsies in ABO-incompatible kidney transplantation. Am J Transplant 2008; 8:86.
  46. Bentall A, Herrera LP, Cornell LD, et al. Differences in chronic intragraft inflammation between positive crossmatch and ABO-incompatible kidney transplantation. Transplantation 2014; 98:1089.
  47. Tobian AA, Shirey RS, Montgomery RA, et al. ABO antibody titer and risk of antibody-mediated rejection in ABO-incompatible renal transplantation. Am J Transplant 2010; 10:1247.
  48. Pollinger HS, Stegall MD, Gloor JM, et al. Kidney transplantation in patients with antibodies against donor HLA class II. Am J Transplant 2007; 7:857.
  49. Bartel G, Wahrmann M, Exner M, et al. Determinants of the complement-fixing ability of recipient presensitization against HLA antigens. Transplantation 2007; 83:727.
  50. OPTN/SRTR 2012 Annual Data Report http://srtr.transplant.hrsa.gov/annual_reports/2012/ (Accessed on November 25, 2014).
  51. Bray RA, Nolen JD, Larsen C, et al. Transplanting the highly sensitized patient: The emory algorithm. Am J Transplant 2006; 6:2307.
  52. Pei R, Lee JH, Shih NJ, et al. Single human leukocyte antigen flow cytometry beads for accurate identification of human leukocyte antigen antibody specificities. Transplantation 2003; 75:43.
  53. El-Awar N, Lee J, Terasaki PI. HLA antibody identification with single antigen beads compared to conventional methods. Hum Immunol 2005; 66:989.
  54. van den Berg-Loonen EM, Billen EV, Voorter CE, et al. Clinical relevance of pretransplant donor-directed antibodies detected by single antigen beads in highly sensitized renal transplant patients. Transplantation 2008; 85:1086.
  55. Takemoto SK, Zeevi A, Feng S, et al. National conference to assess antibody-mediated rejection in solid organ transplantation. Am J Transplant 2004; 4:1033.
  56. Fuggle SV, Martin S. Toward performing transplantation in highly sensitized patients. Transplantation 2004; 78:186.
  57. Orandi BJ, Luo X, Massie AB, et al. Survival Benefit with Kidney Transplants from HLA-Incompatible Live Donors. N Engl J Med 2016; 374:940.
  58. Jordan SC, Pescovitz MD. Presensitization: the problem and its management. Clin J Am Soc Nephrol 2006; 1:421.
  59. Jordan S, Cunningham-Rundles C, McEwan R. Utility of intravenous immune globulin in kidney transplantation: efficacy, safety, and cost implications. Am J Transplant 2003; 3:653.
  60. Jordan SC, Tyan D, Czer L, Toyoda M. Immunomodulatory actions of intravenous immunoglobulin (IVIG): potential applications in solid organ transplant recipients. Pediatr Transplant 1998; 2:92.
  61. Kazatchkine MD, Kaveri SV. Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin. N Engl J Med 2001; 345:747.
  62. Toyoda M, Pao A, Petrosian A, Jordan SC. Pooled human gammaglobulin modulates surface molecule expression and induces apoptosis in human B cells. Am J Transplant 2003; 3:156.
  63. Toyoda M, Zhang XM, Petrosian A, et al. Inhibition of allospecific responses in the mixed lymphocyte reaction by pooled human gamma-globulin. Transpl Immunol 1994; 2:337.
  64. Toyoda M, Zhang X, Petrosian A, et al. Modulation of immunoglobulin production and cytokine mRNA expression in peripheral blood mononuclear cells by intravenous immunoglobulin. J Clin Immunol 1994; 14:178.
  65. Montgomery RA, Zachary AA, Racusen LC, et al. Plasmapheresis and intravenous immune globulin provides effective rescue therapy for refractory humoral rejection and allows kidneys to be successfully transplanted into cross-match-positive recipients. Transplantation 2000; 70:887.
  66. Sonnenday CJ, Ratner LE, Zachary AA, et al. Preemptive therapy with plasmapheresis/intravenous immunoglobulin allows successful live donor renal transplantation in patients with a positive cross-match. Transplant Proc 2002; 34:1614.
  67. Schweitzer EJ, Wilson JS, Fernandez-Vina M, et al. A high panel-reactive antibody rescue protocol for cross-match-positive live donor kidney transplants. Transplantation 2000; 70:1531.
  68. Gloor JM, DeGoey SR, Pineda AA, et al. Overcoming a positive crossmatch in living-donor kidney transplantation. Am J Transplant 2003; 3:1017.
  69. Jordan SC, Vo A, Bunnapradist S, et al. Intravenous immune globulin treatment inhibits crossmatch positivity and allows for successful transplantation of incompatible organs in living-donor and cadaver recipients. Transplantation 2003; 76:631.
  70. Jordan SC, Vo AA, Peng A, et al. Intravenous gammaglobulin (IVIG): a novel approach to improve transplant rates and outcomes in highly HLA-sensitized patients. Am J Transplant 2006; 6:459.
  71. Casadei DH, del C Rial M, Opelz G, et al. A randomized and prospective study comparing treatment with high-dose intravenous immunoglobulin with monoclonal antibodies for rescue of kidney grafts with steroid-resistant rejection. Transplantation 2001; 71:53.
  72. Luke PP, Scantlebury VP, Jordan ML, et al. Reversal of steroid- and anti-lymphocyte antibody-resistant rejection using intravenous immunoglobulin (IVIG) in renal transplant recipients. Transplantation 2001; 72:419.
  73. Rocha PN, Butterly DW, Greenberg A, et al. Beneficial effect of plasmapheresis and intravenous immunoglobulin on renal allograft survival of patients with acute humoral rejection. Transplantation 2003; 75:1490.
  74. Glotz D, Haymann JP, Sansonetti N, et al. Suppression of HLA-specific alloantibodies by high-dose intravenous immunoglobulins (IVIg). A potential tool for transplantation of immunized patients. Transplantation 1993; 56:335.
  75. Tyan DB, Li VA, Czer L, et al. Intravenous immunoglobulin suppression of HLA alloantibody in highly sensitized transplant candidates and transplantation with a histoincompatible organ. Transplantation 1994; 57:553.
  76. Glotz D, Antoine C, Julia P, et al. Desensitization and subsequent kidney transplantation of patients using intravenous immunoglobulins (IVIg). Am J Transplant 2002; 2:758.
  77. Jordan SC, Tyan D, Stablein D, et al. Evaluation of intravenous immunoglobulin as an agent to lower allosensitization and improve transplantation in highly sensitized adult patients with end-stage renal disease: report of the NIH IG02 trial. J Am Soc Nephrol 2004; 15:3256.
  78. Vo AA, Lukovsky M, Toyoda M, et al. Rituximab and intravenous immune globulin for desensitization during renal transplantation. N Engl J Med 2008; 359:242.
  79. Vo AA, Peng A, Toyoda M, et al. Use of intravenous immune globulin and rituximab for desensitization of highly HLA-sensitized patients awaiting kidney transplantation. Transplantation 2010; 89:1095.
  80. Vo AA, Toyoda M, Peng A, et al. Effect of induction therapy protocols on transplant outcomes in crossmatch positive renal allograft recipients desensitized with IVIG. Am J Transplant 2006; 6:2384.
  81. Schiff RI, Williams LW, Nelson RP, et al. Multicenter crossover comparison of the safety and efficacy of Intraglobin-F with Gamimune-N, Sandoglobulin, and Gammagard in patients with primary immunodeficiency diseases. J Clin Immunol 1997; 17:21.
  82. Warren DS, Zachary AA, Sonnenday CJ, et al. Successful renal transplantation across simultaneous ABO incompatible and positive crossmatch barriers. Am J Transplant 2004; 4:561.
  83. Stegall MD, Gloor J, Winters JL, et al. A comparison of plasmapheresis versus high-dose IVIG desensitization in renal allograft recipients with high levels of donor specific alloantibody. Am J Transplant 2006; 6:346.
  84. Zachary AA, Montgomery RA, Ratner LE, et al. Specific and durable elimination of antibody to donor HLA antigens in renal-transplant patients. Transplantation 2003; 76:1519.
  85. Montgomery RA, Lonze BE, King KE, et al. Desensitization in HLA-incompatible kidney recipients and survival. N Engl J Med 2011; 365:318.
  86. Gloor JM, DeGoey S, Ploeger N, et al. Persistence of low levels of alloantibody after desensitization in crossmatch-positive living-donor kidney transplantation. Transplantation 2004; 78:221.
  87. Haas M, Böhmig GA, Leko-Mohr Z, et al. Peri-operative immunoadsorption in sensitized renal transplant recipients. Nephrol Dial Transplant 2002; 17:1503.
  88. Lorenz M, Regele H, Schillinger M, et al. Peritransplant immunoadsorption: a strategy enabling transplantation in highly sensitized crossmatch-positive cadaveric kidney allograft recipients. Transplantation 2005; 79:696.
  89. Mulley WR, Hudson FJ, Tait BD, et al. A single low-fixed dose of rituximab to salvage renal transplants from refractory antibody-mediated rejection. Transplantation 2009; 87:286.
  90. Everly MJ, Everly JJ, Susskind B, et al. Bortezomib provides effective therapy for antibody- and cell-mediated acute rejection. Transplantation 2008; 86:1754.
  91. Locke JE, Magro CM, Singer AL, et al. The use of antibody to complement protein C5 for salvage treatment of severe antibody-mediated rejection. Am J Transplant 2009; 9:231.
  92. Lefaucheur C, Nochy D, Andrade J, et al. Comparison of combination Plasmapheresis/IVIg/anti-CD20 versus high-dose IVIg in the treatment of antibody-mediated rejection. Am J Transplant 2009; 9:1099.
  93. Haas M, Montgomery RA, Segev DL, et al. Subclinical acute antibody-mediated rejection in positive crossmatch renal allografts. Am J Transplant 2007; 7:576.
  94. Haririan A, Nogueira J, Kukuruga D, et al. Positive cross-match living donor kidney transplantation: longer-term outcomes. Am J Transplant 2009; 9:536.
  95. Barbosa D, Kahwaji J, Puliyanda D, et al. Polyomavirus BK Viremia in Kidney Transplant Recipients After Desensitization With IVIG and Rituximab. Transplantation 2013.
  96. Delmonico FL, Morrissey PE, Lipkowitz GS, et al. Donor kidney exchanges. Am J Transplant 2004; 4:1628.
  97. de Klerk M, Keizer KM, Claas FH, et al. The Dutch national living donor kidney exchange program. Am J Transplant 2005; 5:2302.
  98. Johnson RJ, Allen JE, Fuggle SV, et al. Early experience of paired living kidney donation in the United kingdom. Transplantation 2008; 86:1672.
  99. Montgomery RA, Zachary AA, Ratner LE, et al. Clinical results from transplanting incompatible live kidney donor/recipient pairs using kidney paired donation. JAMA 2005; 294:1655.
  100. Gentry SE, Segev DL, Montgomery RA. A comparison of populations served by kidney paired donation and list paired donation. Am J Transplant 2005; 5:1914.
  101. Ackerman PD, Thistlethwaite JR Jr, Ross LF. Attitudes of minority patients with end-stage renal disease regarding ABO-incompatible list-paired exchanges. Am J Transplant 2006; 6:83.
  102. Doxiadis II, Smits JM, Persijn GG, et al. It takes six to boogie: allocating cadaver kidneys in Eurotransplant. Transplantation 2004; 77:615.
  103. Claas FH, Witvliet MD, Duquesnoy RJ, et al. The acceptable mismatch program as a fast tool for highly sensitized patients awaiting a cadaveric kidney transplantation: short waiting time and excellent graft outcome. Transplantation 2004; 78:190.